Exelixis Inc.'s pivotal phase III blowup in colorectal cancer (CRC) may have little read-through to an ongoing melanoma study trying the same two drugs plus a third, and investors still have plenty to cheer about in the strong-selling renal carcinoma (RCC) therapy Cabometyx (cabozantinib).